Creso Pharma (ASX:CPH) Canadian subsidiary, Halucenex, completed the enrollment of patients for its phase 2 trial investigating the use of the psychedelic drug psilocybin in patients with treatment-resistant post-traumatic stress disorder.

The study, slated to start on Oct. 12, recruited 20 patients with PTSD who are also afflicted with other mental health conditions, the medical cannabis firm said on Thursday.